Chronic Traumatic Encephalopathy: Update on Current Clinical Diagnosis and Management

Kevin Pierre 1, Kyle Dyson 1, Abeer Dagra 1, Eric Williams 1, Ken Porche 2 and Brandon Lucke-Wold 2,*

1 College of Medicine, University of Florida, Gainesville, FL 32611, USA; kpierre150@ufl.edu (K.P.); kdyson@ufl.edu (K.D.); abeer.dagra@ufl.edu (A.D.); williamseric@ufl.edu (E.W.)
2 Department of Neurosurgery, University of Florida, Gainesville, FL 32608, USA;
ken.porche@neurosurgery.ufl.edu
* Correspondence: brandon.lucke-wold@neurosurgery.ufl.edu

Abstract: Chronic traumatic encephalopathy is a disease afflicting individuals exposed to repetitive neurotrauma. Unfortunately, diagnosis is made by postmortem pathologic analysis, and treatment options are primarily symptomatic. In this clinical update, we review clinical and pathologic diagnostic criteria and recommended symptomatic treatments. We also review animal models and recent discoveries from pre-clinical studies. Furthermore, we highlight the recent advances in diagnosis using diffusor tensor imaging, functional magnetic resonance imaging, positron emission tomography, and the fluid biomarkers t-tau, sTREM2, CCL11, NFL, and GFAP. We also provide an update on emerging pharmaceutical treatments, including immunotherapies and those that target tau acetylation, tau phosphorylation, and inflammation. Lastly, we highlight the current literature gaps and guide future directions to further improve clinical diagnosis and management of patients suffering from this condition.

Keywords: chronic traumatic encephalopathy; new innovations; biomarkers; emerging imaging

1. Introduction

Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease exhibiting a distinct pattern of neuropathological changes associated with repetitive head trauma leading to increased risk of long-term memory and cognition issues [1–16]. This association between repetitive concussive and asymptomatic sub-concussive trauma and early dementia has been recognized for over 90 years now, mostly in context of routine participation in contact sports and military combat, with some reports indicating this observed pathology in people exposed to physical abuse, head-banging, and poorly controlled epilepsy [1,6,8,9,17,18]. Repetitive head trauma causes lesions at traumatic stress points leading to axonal injury, micro-hemorrhages and subsequent loss of blood brain barrier integrity. These insults trigger an inflammatory cascade and a deposition of phosphorylated tau (p-tau) protein, amyloid-beta (Aβ), TDP-43, neurofibrillary triangles, neutrophil neurites, astrocytic tangles, neuronal loss and cerebral atrophy with white matter changes. The cis isoform of the pathogenic p-tau variants catalyzes transformation of normal into pathogenic tau in a process referred to as cistauosis [1,5,6,8–15]. Clinically, CTE presents with a spectrum of symptoms including changes in behavior, cognition and motor symptoms like impulsivity, paranoia, rage behaviors, headaches, memory deficits, impaired attention, dysphagia, dysarthria, and coordination problems [1–7,9–14,17,18]. The evidence shows that CTE begins focally in cerebral cortex and over the decades, slowly progresses to involve widespread regions of medial temporal lobe, basal ganglia, diencephalon, and brainstem. Progression of CTE has been described in four pathological stages. Stage 1 is characterized by isolated perivascular centers of p-tau and neurofibrillary tangle depositions primarily in the sulcal depths. Stage 2 presents with more frequent pathologic patchy deposition at the depths of the sulci and neurofibrillary tangles primarily dispersed...
throughout superficial cortical layers. These depositions continue spreading in the following stages. However, the hallmark of stages 3 and 4 is a significantly decreasing brain weight with increasing severity of cognitive abnormalities. Stage 3 is characterized by the initial brain weight reduction due to thinning of the corpus callosum, atrophy of the cerebral cortex, mamillary bodies, thalamus, and hypothalamus, with depigmentation of the locus coeruleus and substantia nigra. Finally, in stage 4, there is significant reduction in brain weight due to widespread cerebral cortical atrophy of the medial temporal lobe, thalamus, hypothalamus, and mamillary bodies, along with complete depigmentation of substantia nigra [1,5,8,11–15].

Although neuropathological clinical manifestations and some histological analysis overlaps between CTE and other neurodegenerative diseases, specifically Alzheimer’s disease (AD), the emerging evidence from autopsy studies have shown distinct features that distinguish CTE from other tauopathies like AD specifically in terms of the pattern of neurofibrillary tangles and other proteins [1,5,8,12,13]. For example, Beta-amyloid (Aβ) plaques are found in 52% of individuals with CTE, however when they occur, they are typically less dense and more diffuse than in Alzheimer’s disease [5,13]. While tau protein deposition occurs primarily in the superficial cortical layers with perivascular predilection in CTE, the Alzheimer’s disease is characterized by predominant neurofibrillary tangles in deep cortical laminae [7,16].

Genetic and psychosocial risk factors associated with CTE have also been investigated recently to explore the pathogenesis of CTE as a multifactorial problem. Here, repeated mild brain trauma leads to trauma-induced tau hyperphosphorylation followed by activation of a various potential second-risk determinants like involvement of apolipoprotein E (ApoE) e4 allele and loss of TDP-43 nuclear function. These changes can be associated with inhibition of neuronal growth following brain injury [5,6,9,11,12,15,16]. Moreover, the progression of this neurodegenerative pathology is also influenced by the age at which an individual begins playing contact sports, and even exposure to performance-enhancing drugs [5,11,16]. Another hypothesis suggests that while initial tau deposition happens in a trauma-dependent mechanism, the continued spread of depositions possibly occurs via trauma-independent mechanisms possibly associated with increased level of inflammation, neuronal tau secretion, damaged tau clearance in extracellular cerebrospinal fluid and leakage of the BBB [1,5,8,11,14,16,19].

Like most neurodegenerative diseases, CTE can only be diagnosed by postmortem neuropathologic examination of the brain tissue revealing pathognomonic lesions consisting of irregular patterns of perivascular p-tau aggregates in neurons, astrocytes, and cell processes at the depths of the cortical sulci [1,5,8,12–14]. Recent studies have shown increased inflammatory involvement in CTE, specifically CD68 immunoreactive microglia and increased levels of the cytokine CCL11 in the frontal cortex compared to controls or subjects with AD [1,5,20]. These findings along with attempts to find biomarkers unique to CTE on neuroimaging offer implications for development of in-vivo methods of clinical diagnosis of CTE, hence opening doors for opportunities for early identification and progression management that improves overall outcomes.

2. Innovations in Diagnosis

The diagnostic criteria and neuropathologic features of CTE are well defined but perfecting in-vivo diagnosis of CTE remains elusive; CTE is only definitively diagnosed at autopsy. Studies into neurobehavioral commonalities, neuropathology, cognitive and functional symptomatology, imaging findings, and biomarkers illuminate our perspective on in-vivo diagnosis and facilitate improved characterization of the spectrum of CTE. These diagnostic innovations are summarized in Table 1.
Table 1. Innovation in Diagnosis of CTE.

| Methods                                      | Relevance                                                                 |
|----------------------------------------------|--------------------------------------------------------------------------|
| **Clinical Diagnostic Criteria**             |                                                                          |
| Trauma encephalopathy syndrome (TES)         | Five criteria to make clinical diagnosis                                  |
|                                              | History of multiple impacts                                               |
|                                              | Absence of comorbid disease that could account for symptoms               |
|                                              | Presence of symptoms for at least 12 months                               |
|                                              | Presence of at least one core clinical feature (mood, cognitive or behavioral impairment) |
|                                              | Presence of supportive features like decline over 12+ months, headache, or impulsivity |
| **Imaging**                                  |                                                                          |
| Diffusion tensor imaging (DTI)               | Detection of white matter integrity                                       |
| Blood oxygenation level–dependent MRI, also known as functional (fMRI) | Detection of changes in hemoglobin oxygenation with brain task function correlation |
| PET                                          | Used with CTE imaging biomarkers FDDNP, T807, AV1451, and flortaucipir. Regions of uptake depend on the specific biomarker |
| **Fluid Biomarkers**                         |                                                                          |
| t-tau                                        | Marker of neuroinflammation, endoplasmic reticulum, and oxidative stress |
| sTREM2                                       | Marker of microglial activation                                           |
| CCL11 (chemokine)                            | Inflammatory marker associated with neurodegeneration                     |
| Neurofilament light chain (NFL)              | Marker increased in axonal injury                                         |
| Glial fibrillary acidic protein (GFAP)        | Glial-derived biomarker                                                  |

2.1. Clinical Diagnostic Criteria

The core diagnostic features present in more than 70% of confirmed CTE cases without comorbidities falls into the three domains: cognitive, behavioral, mood [21,22]. Cognitive symptoms include impairments in memory and executive functioning. Behavioral symptoms include verbal and physical violent behavior, explosivity, and impulsivity. Mood symptoms often include depression. Differentiation of these various manifestations of CTE from other forms of TBI like post-concussive syndrome, remains difficult, and it is unknown whether they share neuropathological features [21]. Although clinical features can be characterized in-vivo, definitive diagnosis of CTE still requires an autopsy [23], prompting Montinegro et al. to propose a new diagnostic criterion, known as trauma encephalopathy syndrome (TES). TES as a diagnostic criterion is based on the clinical features commonly found in CTE and consist of five criteria: history of multiple impacts, absence of comorbid disease that could account for symptoms, presence of symptoms for at least 12 months, presence of at least one core clinical feature (e.g., Mood, cognitive or behavioral impairment), and the presence of supportive features like decline over at least 12 months, headache, or impulsivity [22]. Still, there remains various proposed clinical classifications and varying diagnostic criteria; consensus within the academic community has not been reached [24].
2.2. Diagnostic Imaging

While CTE remains a histologic diagnosis, identification of radiographic signs and correlates of disease severity remains a high priority. MRI is the imaging modality of choice for evaluating structural changes in chronic TBI and CTE due to superior sensitivity compared to computed tomography (CT) and the ability to detect diffuse axonal injury. Unfortunately, recurrent structural findings, such as grey matter atrophy, ventricular enlargement, and cavum septum pellucidum, are not specific to CTE [25] and structural findings are therefore not sufficient to diagnose CTE.

Use of diffusion tensor imaging (DTI) to assess white matter integrity has become a popular tool for assisting in the diagnosis of CTE [26]. Research indicates it may be useful in determining the relationship between cognitive deficits and TBI and in distinguishing the spectrum of brain injury, even when the injury was sustained years prior [27]. Post-mortem analysis has confirmed the relationship between axonal damage and decreased fractional anisotropy (FA) [28].

Blood oxygenation level-dependent MRI, also known as functional (fMRI) can detect changes in the oxygenation of hemoglobin while correlating to brain function during a specific task. Although the use of BOLD fMRI for the study of TBI presents challenges due decreased cerebral blood flow found in TBI, it remains a novel tool for analyzing the activity of specific regions of the brain [27]. Significant developments are taking place with the use of PET for diagnosing CTE [12] using ligands that bind pathology in CTE. The most well-studied is FDDNP, which binds to neurofibrillary tangles. However, it is non-specific because it binds to β-amyloid in addition to hyperphosphorylated tau [29]. Other tracers include T807, AV1451, and flortaucipir. Though nascent in their development, they are emerging as promising tools within the field of imaging biomarkers for CTE. While studies investigating this imaging modality have shown varied regions of uptake, they have consistently demonstrate increased tracer uptake in the limbic system and temporal lobe. However, evidence for tracer uptake in cortical regions widely varies [29].

2.3. Fluid Biomarkers

The identification of fluid biomarkers from blood or CSF is under active investigation for pre-morbid diagnosis of CTE. While no single fluid biomarker is sufficient or approved for diagnosis, several studies are continually investigating further fluid biomarker candidates [1]. Although also associated with chronic neurodegenerative disease such as AD, preliminary research supports the use of plasma t-tau as a marker of injury severity following repetitive head trauma [1,30]. Total plasma and CSF tau concentrations have been shown to correlate with increased exposure to athletic head impacts in multiple studies, and a plasma concentration ≥3.56 pg/mL has been suggested as a threshold to reliably distinguish NFL players from healthy controls [30–32]. Stern et al. demonstrated that exosomal tau could also reliably differentiate former NFL players from healthy controls and that levels correlate with cognitive and psychomotor decline [33]. Triggering receptor expressed on myeloid cells 2 (TREM2) is a protein involved in microglia resolution of CNS inflammation and is a known correlate of AD severity [34,35]. Microglia are known mediators of neuroinflammation and have been found to contribute to the accumulation of tau in CTE [36]. Examining soluble TREM2 (sTREM2) concentrations in the CSF as a marker of microglial activation, Alosco et al. found sTREM2 correlated with total tau levels, and strengthened the relationship with tau and head trauma when included in regression models. Microglia also express cognate receptors for the chemokine CCL11/eotaxin, an inflammatory marker associated with neurodegeneration. CCL11 has been shown to be significantly elevated within the dorsolateral frontal cortex (DLFC) of former American football players, with a non-significant increase within the CSF, and could reliably differentiate CTE from AD [20]. Other promising fluid biomarkers under investigation include neurofilament light chain (NFL) and glial fibrillary acidic protein (GFAP).
3. Innovations in Clinically Oriented Treatment

Prevention of TBI remains the only method of prevention. Within the contact sports, which are common facilitators of repetitive mild TBI (rmTBI), preventative measures include contact rule changes and protective equipment, with an acknowledgement that no protective equipment can prevent a concussion [18]. Immediate removal from play with strict supervised return to play guidelines and proper medical management remains a crucial element in prevention of second impact syndrome and other sequelae [33].

Treatment of CTE is currently mainly supportive. However, recently elucidated understandings of neurobiological mechanisms in rodent models have led to advances in treatment development. We summarize the currently recommended treatments and promising innovations in the following paragraphs and Table 2.

### Table 2. Innovation in Treatment of CTE.

| Specific Agents                      | Mechanism         |
|--------------------------------------|-------------------|
| **Current Treatments**               |                   |
| Cognitive rehabilitation therapy     | Supportive therapy|
| Motor therapy                        |                   |
| Mood and behavior therapy            |                   |
| Mindfulness                          |                   |
| Mediterranean diet                   |                   |
| Aerobic exercise                     |                   |
| Vestibular rehabilitative therapy    |                   |
| Occupational-ocular therapy         |                   |
| Memory impairment medications—galantamine, donezepil, and rivastigmine | |
| Stimulants—methylphenidate           |                   |
| Dopamine agonists—carbidopa/levodopa, pramipexole, amantadine, memantine | |
| Antidepressive/anxiety medications—sertraline and escitalopram | |
| **Potential Treatments**             |                   |
| Salsalate                            | Targets tau acetylation |
| methylene blue                       |                   |
| histone deacetylase 6 (HDAC)         |                   |
| sirtuins (SIRT1 and SIRT2)           |                   |
| Dimethyl fumarate (DMF)              |                   |
| Lithium                              |                   |
| GSK3 inhibitor L803-mts              | Targets tau phosphorylation |
| Intravenous simvastatin              |                   |
| roscovitine (and its derivative CR-8) |                   |
| anti-p-Tau antibody                  | Immunotherapy     |
| antibody 6C5                         |                   |
| OCH                                  |                   |
| salubrinal                           | Targets inflammation |
| calpain-2 inhibitor                  |                   |
| 2-arachidonoylglycerol (2-AG)        |                   |
3.1. Recommended Supportive Treatments

Non-pharmaceutical management recommendations include cognitive rehabilitation, motor therapy, mood and behavior therapy, mindfulness, the Mediterranean diet, and aerobic exercise. Vestibular rehabilitative therapy is also recommended for those with inner ear injury resultant from repetitive TBI. Occupational-ocular therapy is recommended for those with visual disturbances. There are no FDA-approved medications for CTE. They are used “off-label” and primarily target symptomology. Drugs used for memory impairment parallel those used in Alzheimer’s disease like galantamine, donepezil, and rivastigmine. In addition to stimulants like methylphenidate, dopamine agonists like carbidopa/levodopa, pramipexole amantadine, memantine, may treat apathy. Furthermore, these stimulants can treat impaired attention. Depression and anxiety medications include sertraline and escitalopram, though they with caution considering its side effect of suicidality as suicide is well-documented in CTE.

Furthermore, it is recommended to optimize drug regimens to minimize drugs interactions and reduce those that may exacerbate symptoms and cause further cognitive impairments, like sedatives and anticholinergics [37].

Considering the recent advances in the understanding of the molecular and inflammatory cascades leading to progressive neurodegeneration, pre–clinical studies paving the way for clinical trials for patients with CTE [12].

3.2. Review of Pre-Clinical Animal Models

CTE is characterized by progressive neurodegeneration in the absence of further trauma through incompletely understood secondary injury cascades. A better understanding of these molecular pathways and optimized treatment development would be facilitated using animal models representing CTE. While several well-characterized animal models, like the non-impact head acceleration, blast wave, weight drop, fluid percussion, and controlled cortical impact (CCI) models exist for traumatic brain injury, animal model development for CTE is still in the early stages as none fully reflect the known progressive pathological, neurocognitive, and psychiatric findings. Still, many models inflicting repetitive mild TBI reflect some findings like neurofibrillary tangles, Aβ, phosphorylated tau, and TDP-43 deposition, microgliosis, astrogliosis, ER stress, glutamate excitotoxicity, and white matter changes, as well as the sequelae involving progressive cognitive impairment and mood changes [38–53].

3.3. Targeting Tau Acetylation

Pre-clinical studies have investigated the treatment of tauopathies by targeting known molecular pathways. P-tau accumulation results from tau phosphorylation, preceded by ac-tau post-translational acetylation, which is likely a result of neuroinflammation, endoplasmic reticulum, and oxidative stress [49,54,55]. Studies investigating the treatment of tauopathies have largely targeted this pathway. For example, salsalate reduced inflammation, promoted neuroprotection and neurogenesis through gene upregulation, prevented hippocampal atrophy, and led to functional recovery in acetylation in mTBI rodent models by reducing p300 lysine acetyltransferase, inhibiting tau acetylation on lysine 174, and inhibiting microgliosis [55–57]. Salsalate treatment also proved similar results in a rodent model of frontotemporal dementia [55]. Similarly, methylene blue, which modulates K280/K281 acetylation activity, promoted neuroprotection, reduced behavioral deficits and mood changes, and minimizes neuronal degeneration, neuroinflammation, lesion volume, microgliosis, and mitochondrial dysfunction in TBI rodent models [58–64]. In-vitro studies demonstrated that histone deacetylase 6 (HDAC) and sirtuins (SIRT1 and SIRT2) promoted tau deacetylation, potentially representing an additional treatment methodology targeting the same pathway mechanism differently [65,66].
3.4. Targeting Tau Phosphorylation

Kinase inhibition has also been successfully explored in pre-clinical models. Glycogen synthase 3 beta (GSK-3B) which is activated by p-tau to cause further tau phosphorylation, promote amyloid-b related cell death, and downregulate antioxidant defenses like Nuclear factor E2-related factor 2 (Nrf2) [67–69]. Dimethyl fumarate (DMF) modulated GSK-3B activity, induced the Nrf2 transcriptional signature, and attenuated astrogliosis and microgliosis in tauopathy mouse models [70]. Lithium, which blocks GSK magnesium binding, promotes GSK phosphorylation, and blocks receptor tyrosine kinase activity, reduced neurodegeneration, maintained the blood-brain barrier integrity, improved cognitive outcomes, and reduced lesion sizes in TBI mouse models [71–77].

Additionally, Lithium may treat many CTE features like mood, impulsivity, suicidal ideation, and depression [78]. Valproic acid, alone or administered with lithium, results in neuroprotection and improved functional outcomes [75,79]. The GSK3 inhibitor L803-mts prevented TBI-induced depression in mTBI weight drop rodent models [72]. Intravenous simvastatin which activates the receptor tyrosine kinase to block GSK3, improved cognitive outcomes, reduced neuroinflammation, neurodegeneration, and promoted neuroregeneration in rodent models [80–82].

Several studies demonstrated that roscovitine and its derivative CR-8, cyclin dependent kinase (CDK) inhibitors, reduced neuroinflammation and neurodegeneration while improving functional outcomes in TBI rat models [83]. A study showed that the combined use of Lithium and roscovitine had more profound reductions in cortical and blood p-tau when used in combination rather than when used alone in a mouse model of repetitive mild TBI [50].

3.5. Immunotherapy

Immunotherapy by the use of monoclonal antibodies has also been studied in pre-clinical studies investigating tauopathies. Notably, a recent study demonstrated that the delivery of an adeno-associated virus (AAV) vector coding for an anti-pTau antibody reduced CNS pTau levels in rodent models of repeated traumatic brain injury [84]. An in-vitro study demonstrated that several tau antibodies successfully prevented neuronal tau uptake. The antibody 6C5 prevented interneuronal spreading and progression of aggregation after cellular uptake [85]. In an effort to avoid targeting the trans isoform of p-tau that is important for normal cellular activity, antibodies developed specific to the pathogenic cis-P-tau that develops after TBI demonstrated reductions in tauopathy and improved structural and functional outcomes [86–88].

3.6. Targeting Inflammation

Studies have also targeted the complex inflammatory cascade and metabolic changes occurring in CTE. A recent study investigated the use of 4-[2-[2-(3,4-dimethoxyphenyl)-vinyl]-6-ethyl-4-oxo-5-phenyl-4H-pyrimidine-1-il]bensulfamide (OCH, a pyrimidine derivative) which is proposed to preserve mitochondrial function and proper ATP synthesis following TBI. In rodent models of repetitive TBI, OCH improved ATP-generation, respiratory intensity, and cerebral blood flow while decreasing glycolysis intensity, CTE biomarker concentrations, and β-amyloid levels. It also preserved sensorimotor function [89]. Administration of the salubrinal (SAL), a stress modulator, significantly reduced ER stress, oxidative stress, pro-inflammatory cytokines, and inducible nitric oxide synthase while preventing impulsive-like behavior in rodent models of repetitive TBI [90]. Calpain-2 is proposed to contribute to neurodegeneration following TBI. The use of a selective calpain-2 inhibitor, (C2I) significantly reduced calpain-2 activation, prevented increased tau phosphorylation and TDP-43 changes, prevented astrogliosis and microgliosis, and eliminated cognitive impairment in a rodent model of repeated traumatic brain injury [91]. Several studies have shown that the ketogenic diet enhances cognitive, motor, and pathological outcomes in rodent TBI models [92]. Pre-clinical studies have also indicated that increased
recovery times in rodents improve outcomes, consistent with similar studies in human populations [93,94].

Lastly, studies have investigated the role of arachidonic acid’s metabolic product 2-arachidonoylglycerol, which inhibits inflammation started by NF-kB (2-AG). Inhibition of monoacylglycerol lipase (MAGL), which metabolizes 2-AG, significantly reduced neurodegeneration, tau phosphorylation and TDP-43 aggregation, astroglisis, and proinflammatory cytokines while improving cognitive outcomes in a repetitive mild TBI rodent model [95]. Furthermore, 2-AG improved blood-brain barrier integrity and reduced inflammatory cytokine expression when administered exogenously in a CHI rodent model [96].

4. Future Discoveries

CTE has gained significant media attention in recent years. Despite significant effort, methods for pre-mortem diagnosis and treatment remain elusive. While there are several proposed clinical diagnostic criteria, there is unfortunately no consensus among the scientific community on which to use. Furthermore, there is little research assessing these criteria’s diagnostic validity.

Imaging modalities are also similarly limited. While radiographic findings are consistently identified in patients with overt clinical disease, their diagnostic utility remains unclear considering small sample sizes, inconsistent use of imaging modality, little histological correlation, and confounding and unknown effects (e.g., gender, intelligence quotient, education, genetic polymorphisms). Small sample sizes are a particularly limiting factor considering the heterogeneity of CTE among individuals. Diagnostic studies vary widely in analysis methodology, making interpretation and inter-study comparison difficult. Only two studies have directly compared histologic and imaging analyses [28,97], which would support validation of imaging-based diagnostics. Many studies do not use age-matched control groups, rendering differentiation of normal-aging associated neurological changes from CTE difficult. Many studies, particularly those analyzing contact sports, do not include females, preventing the study of gender-based outcomes of chronic TBI. Therefore, future directions to improve radiographic diagnosis of patients with CTE include: validation of diagnostic criteria; adequately controlled imaging studies with increased sample sizes and greater statistical power; inclusion of female study participants; consistent imaging methodologies; consistent use of age-matched control groups; and neuropathological evaluation to directly correlate imaging and pathologic findings. Furthermore, more studies investigating additional, more specific tau ligands like flortaucapir are needed [98]. We look forward to the results of the DIAGNOSE-CTE project, which will perform longitudinal investigations in athletes to validate various diagnostic tests [99].

While many blood and CSF biomarkers are well-characterized for TBI, few biomarkers have been studied specifically for CTE [100]. Identification of reliable biomarkers may support early diagnosis, prognostication, monitoring of disease progression, evaluation of treatment response, and support linking pathological disease burden with clinical symptomology. Considering that the pathology of CTE significantly overlaps with other tauopathies, investigating validated biomarkers in the context of CTE is a reasonable next approach [101]. While still premature, next-generation imaging modalities, such as engineered macrophages used to image micro-metastases, have potential applications to any disease state involving an inflammatory state and may have applicability to neurodegenerative diseases such as CTE [102].

Currently, there are no approved drugs that improve pathological and functional outcomes in patients with CTE. Preclinical studies have largely shown promising results in the treatment of CTE. While there are ongoing clinical trials for treatments in other tauopathies like Alzheimer’s, there are very little for CTE. Furthermore, very few pre-clinical studies explore these treatments in rodent models specific for CTE, likely due to their recent advent. Therefore, in addition to the need for continued research for rodent models accurately reflecting CTE pathology, there is a need for further treatment studies using these animal models. There is an increasingly appreciated role of the immune system in traumatic
brain injury. Microglia have remained the predominant focus, however, the relative involvement of peripheral immune cells recruited to CNS after traumatic injury is unknown and further investigations into this component of disease pathogenesis may reveal novel therapeutics [97]. Other topics worthy of future investigation include development of personalized monoclonal antibodies and enhancement of blood brain barrier permeability through unilateral focused and low-intensity pulsed ultrasound methods [103].

Considering a lack of treatment options, the best treatment method for CTE remains unclear. Therefore, continued research on the efficacy of protective equipment, development of enhanced protective equipment, continued enforcement and further development of sport contact roles, and improvements in enforcement of return to play protocols is needed [104].

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: Brandon Lucke-Wold has a pending patent for 3-phenyl-N-[2,2,2-trichloro-1-[[8-quinoxylylamine]thioxymethyl amino]ethyl]-2-propenamide (salubrinal) (Patent #: US2020001-6145A1). All other authors declare no conflict of interest.

References
1. Hainline, B.; Stern, R.A. Sports Neurology; Elsevier: San Diego, CA, USA; Amsterdam, The Netherlands, 2018.
2. Montenigro, PH.; Corp, D.T.; Stein, T.D.; Cantu, R.C.; Stern, R.A. Chronic traumatic encephalopathy: Historical origins and current perspective. Ann. Rev. Clin. Psychol. 2015, 11, 309–330. [CrossRef]
3. McKee, A.C.; Cantu, R.C.; Nowinski, C.J.; Hedley-Whyte, E.T.; Gavett, B.E.; Hudson, A.E.; Santini, V.E.; Lee, H.-S.; Kubilus, C.A.; Stern, R.A. Chronic traumatic encephalopathy in athletes: Progressive tauopathy after repetitive head injury. J. Neuropathol. Exp. Neurol. 2009, 68, 709–735. [CrossRef]
4. Perrine, K.; Helcer, J.; Tsouris, A.J.; Pisapia, D.J.; Stieg, P. The Current Status of Research on Chronic Traumatic Encephalopathy. World Neurosurg. 2017, 102, 533–544. [CrossRef]
5. McKee, A.C.; Alosco, M.L.; Huber, B.R. Repetitive Head Impacts and Chronic Traumatic Encephalopathy. Neurosurg. Clin. N. Am. 2016, 27, 529–535. [CrossRef]
6. Geddes, J.F.; Vowles, G.H.; Nicoll, J.A.R.; Révész, T. Neuronal cytoskeletal changes are an early consequence of repetitive head injury. Acta Neuropathol. 1999, 98, 171–178. [CrossRef]
7. Ling, H.; Neal, J.W.; Revesz, T. Evolving concepts of chronic traumatic encephalopathy as a neuropathological entity. Neuropathol. Appl. Neurobiol. 2017, 43, 467–476. [CrossRef] [PubMed]
8. McKee, A.C.; Cairns, N.J.; Dickson, D.W.; Folkerth, R.D.; Keene, C.D.; Litvan, I.; Perl, D.P.; Stein, T.D.; Vonsattel, J.-P.; Stewart, W.; et al. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol. 2016, 131, 75–86. [CrossRef] [PubMed]
9. Smith, D.H.; Johnson, V.E.; Trojanowski, J.Q.; Stewart, W. Chronic traumatic encephalopathy—Confusion and controversies. Nat. Rev. Neuro. 2019, 15, 179–183. [CrossRef] [PubMed]
10. Chen, L. What triggers tauopathy in chronic traumatic encephalopathy? Neural Regen. Res. 2018, 13, 985–986. [CrossRef] [PubMed]
11. Inserrea, C.J.; DeVrieze, B.W. Chronic Traumatic Encephalopathy: StatPearls Publishing LLC: Treasure Island, FL, USA, 2021.
12. Thamaratnam, T.; Iskandar, M.A.; Tabobondung, T.C.; Tobbia, I.; Gopee-Ramanan, P.; Tabobondung, T.A. Chronic Traumatic Encephalopathy in Professional American Football Players: Where Are We Now? Front. Neurol. 2018, 9, 445. [CrossRef] [PubMed]
13. Huber, B.R.; Alosco, M.L.; Stein, T.D.; McKee, A.C. Potential Long-Term Consequences of Concussive and Subconcussive Injury. Phys. Med. Rehabil. Clin. N. Am. 2016, 27, 503–511. [CrossRef] [PubMed]
14. McKee, A.C.; Stein, T.D.; Kierman, P.T.; Alvarez, V.E. The neuropathology of chronic traumatic encephalopathy. Brain Pathol. 2015, 25, 350–364. [CrossRef]
15. McKee, A.C.; Stern, R.A.; Nowinski, C.J.; Stein, T.D.; Alvarez, V.E.; Daneshvar, D.H.; Lee, H.S.; Wojtowicz, S.M.; Hall, G.; Baugh, C.M.; et al. The spectrum of disease in chronic traumatic encephalopathy. Brain 2013, 136, 3–64. [CrossRef]
16. McCambridge, M.; Stinson, M.J. Advances in chronic traumatic encephalopathy. J. Am. Acad. PA 2020, 33, 39–42. [CrossRef] [PubMed]
17. Roberts, G.W.; Whitwell, H.L.; Acland, P.R.; Bruton, C.J. Dementia in a punch-drunk wife. Lancet 1990, 335, 918–919. [CrossRef]
18. Hof, P.R.; Knabe, R.; Bovier, P.; Bouras, C. Neuropathological observations in a case of autism presenting with self-injury behavior. Acta Neuropathol. 1991, 82, 321–326. [CrossRef]
19. Tagge, C.A.; Fisher, A.M.; Mineva, O.V.; Gaudreau-Balderrama, A.; Moncaster, J.A.; Zhang, X.-L.; Wojnarowicz, M.W.; Casey, N.; Lu, H.; Kokiko-Cocharn, O.N.; et al. Concussion, microvascular injury, and early tauopathy in young athletes after impact head injury and an impact concussion mouse model. *Brain* **2018**, *141*, 422–458. [CrossRef]  
20. Cherry, J.D.; Stein, T.D.; Tripodis, Y.; Alvarez, V.E.; Huber, B.R.; Au, R.; Kiernan, P.T.; Daneshvar, D.H.; Mez, J.; Solomon, T.M.; et al. CCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimer’s disease. *PloS ONE* **2017**, *12*, e018551. [CrossRef]  
21. Jordan, B.D. The clinical spectrum of sport-related traumatic brain injury. *Nat. Rev. Neurol.* **2013**, *9*, 222–230. [CrossRef]  
22. Montenigro, P.H.; Baugh, C.M.; Daneshvar, D.H.; Mez, J.; Budson, A.E.; Au, R.; Katz, D.I.; Cantu, R.C.; Stern, R.A. Clinical subtypes of chronic traumatic encephalopathy: Literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome. *Alzheimers Res. Ther.* **2014**, *6*, 68. [CrossRef]  
23. Saulle, M.; Greenwald, B.D. Chronic traumatic encephalopathy: A review. *Rehabil. Res. Pract.* **2012**, *2012*, 816069. [CrossRef]  
24. Fesharaki-Zadeh, A. Chronic Traumatic Encephalopathy: A Brief Overview. *Front. Neurol.* **2019**, *10*, 713. [CrossRef]  
25. Gandy, S.; Ikonomovic, M.D.; Mitsis, E.; Elder, G.; Ahlers, S.T.; Barth, J.; Stone, J.R.; DeKosky, S.T. Chronic traumatic encephalopathy: Clinical-biomarker correlations and current concepts in pathogenesis. *Mol. Neurodegener.* **2014**, *9*, 37. [CrossRef]  
26. Milani, C.; Jadavji, N. Chronic Traumatic Encephalopathy: Connecting Mechanisms to Diagnosis and Treatment. *J. Young Investig.* **2017**, *2*, 33–40. [CrossRef]  
27. Kraus, M.F.; Susman, T.; Caughlin, B.P.; Walker, C.J.; Sweeney, J.A.; Little, D.M. White matter integrity and cognition in chronic traumatic brain injury: A diffusion tensor imaging study. *Brain* **2007**, *130*, 2508–2519. [CrossRef] [PubMed]  
28. Holleran, L.; Kim, J.H.; Gangolli, M.; Stein, T.; Alvarez, V.; McKee, A.; Brody, D.L. Axonal disruption in white matter underlying cortical sulcus tau pathology in chronic traumatic encephalopathy. *Acta Neuropathol.* **2017**, *133*, 367–380. [CrossRef] [PubMed]  
29. Lee, B.G.; Leavitt, M.J.; Bernick, C.B.; Leger, G.C.; Rabinovic, G.; Banks, S.J. A Systematic Review of Positron Emission Tomography of Tau, Amyloid Beta, and Neuroinflammation in Chronic Traumatic Encephalopathy: The Evidence to Date. *J. Neurotrauma* **2018**, *35*, 2015–2024. [CrossRef] [PubMed]  
30. Alosco, M.L.; Tripodis, Y.; Jarnagin, J.; Baugh, C.M.; Martin, B.; Chaisson, C.E.; Estocho, N.; Song, L.; Cantu, R.C.; Jeromin, A.; et al. Repetitive head impact exposure and later-life plasma total tau in former National Football League players. *Alzheimers Dement.* **2016**, *3*, 7, 33–40. [CrossRef] [PubMed]  
31. Taghdiri, F.; Multani, N.; Tarazi, A.; Naeimi, S.A.; Khodadadi, M.; Esopenko, C.; Green, R.; Colella, B.; Wennberg, R.; Mikulis, D.; et al. Elevated cerebrospinal fluid total tau in former professional athletes with multiple concussions. *Neurology* **2019**, *92*, e2717–e2726. [CrossRef] [PubMed]  
32. Alosco, M.L.; Tripodis, Y.; Fritts, N.G.; Reshegrave, A.; Baugh, C.M.; Conneely, S.; Mariani, M.; Martin, B.M.; Frank, S.; Mez, J.; et al. Cerebrospinal fluid total tau, Aβ, and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration. *Alzheimers Dement.* **2018**, *14*, 1159–1170. [CrossRef] [PubMed]  
33. Stern, R.A.; Tripodis, Y.; Baugh, C.M.; Fritts, N.G.; Martin, B.M.; Chaisson, C.; Cantu, R.C.; Joyce, J.A.; Shah, S.; Ikezu, T.; et al. Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy. *J. Alzheimers Dis.* **2016**, *51*, 1099–1109. [CrossRef] [PubMed]  
34. Sims, R.; van der Lee, S.J.; Naj, A.C.; Bellenguez, C.; Badarinarayanan, N.; Jakobsdottir, J.; Kunkle, B.W.; Boland, A.; Raybould, R.; Bis, J.C.; et al. Rare coding variants in PLCG2, AB3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer’s disease. *Nat. Genet.* **2017**, *49*, 1373–1384. [CrossRef] [PubMed]  
35. Neumann, H.; Takahashi, K. Essential role of the microglial triggering receptor expressed on myeloid cells-2 (TREM2) for central nervous tissue immune homeostasis. *J. Neuroimmunol.* **2007**, *184*, 92–99. [CrossRef]  
36. Cherry, J.D.; Tripodis, Y.; Alvarez, V.E.; Huber, B.; Kiernan, P.T.; Daneshvar, D.H.; Mez, J.; Montenigro, P.H.; Solomon, T.M.; Alosco, M.L.; et al. Microglial neuroinflammation contributes to tau accumulation in chronic traumatic encephalopathy. *Acta Neuropathol. Commun.* **2016**, *4*, 112. [CrossRef] [PubMed]  
37. Cantu, R.; Budson, A. Management of chronic traumatic encephalopathy. *Expert Rev. Neurother.* **2019**, *19*, 1015–1023. [CrossRef] [PubMed]  
38. Albayram, O.; Albayram, S.; Mannix, R. Chronic traumatic encephalopathy—A blueprint for the bridge between neurological and psychiatric disorders. *Transl. Psychiatry* **2020**, *10*, 424. [CrossRef]  
39. Weber, J.T. Experimental models of repetitive brain injuries. *Prog. Brain Res.* **2007**, *161*, 253–261. [PubMed]  
40. Uryu, K.; Laurer, H.; McIntosh, T.; Praticò, D.; Martinez, D.; Leight, S.; Lee, V.M.; Trojanowski, J.Q. Repetitive mild brain trauma accelerates Aβeta deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of Alzheimer amyloidosis. *J. Neurosci.* **2002**, *22*, 446–454. [CrossRef] [PubMed]  
41. Ojo, J.O.; Mouzon, B.; Greenberg, M.B.; Bachmeier, C.; Mullan, M.; Crawford, F. Repetitive mild traumatic brain injury augments tau pathology and glial activation in aged tHtau mice. *J. Neuropathol. Exp. Neurol.* **2013**, *72*, 137–151. [CrossRef] [PubMed]  
42. Mouzon, B.; Chaytow, H.; Cynnen, G.; Bachmeier, C.; Stewart, J.; Mullan, M.; Stewart, W.; Crawford, F. Repetitive mild traumatic brain injury in a mouse model produces learning and memory deficits accompanied by histological changes. *J. Neurotrauma* **2012**, *29*, 2761–2773. [CrossRef] [PubMed]  
43. Huang, L.; Coats, J.S.; Mohd-Yusof, A.; Yin, Y.; Assaad, S.; Muellner, M.J.; Kasper, J.E.; Hartman, R.E.; Dulcic, M.; Donovan, V.M.; et al. Tissue vulnerability is increased following repetitive mild traumatic brain injury in the rat. *Brain Res.* **2013**, *1499*, 109–120. [CrossRef] [PubMed]
44. Luo, J.; Nguyen, A.; Villeda, S.; Zhang, H.; Ding, Z.; Lindsey, D.; Bieri, G.; Castellano, J.M.; Beaupre, G.S.; Wyss-Coray, T. Long-term cognitive impairments and pathological alterations in a mouse model of repetitive mild traumatic brain injury. Front. Neurol. 2014, 5, 12. [CrossRef]

45. DeFord, S.M.; Wilson, M.S.; Rice, A.C.; Clausen, T.; Rice, L.K.; Barabanova, A.; Bullock, R.; Hamm, R.J. Repeated mild brain injuries result in cognitive impairment in B6C3F1 mice. J. Neurotrauma 2002, 19, 427–438. [CrossRef]

46. Kane, M.J.; Angoa-Pérez, M.; Briggs, D.J.; Viano, D.C.; Kreipke, C.W.; Kuhn, D.M. A mouse model of human repetitive mild traumatic brain injury. J. Neurosci. Methods 2012, 203, 41–49. [CrossRef]

47. Mannix, R.; Meehan, W.P.; Mandeville, J.; Grant, P.E.; Gray, T.; Berglass, J.; Zhang, J.; Bryant, J.; Rezaie, S.; Chung, J.Y.; et al. Clinical correlates in an experimental model of repetitive mild brain trauma. Ann. Neurol. 2013, 74, 65–75. [CrossRef] [PubMed]

48. Petraglia, A.L.; Plog, B.A.; Dayawansa, S.; Chen, M.; Dashnaw, M.L.; Czerniecka, K.; Walker, C.T.; Viterise, T.; Hyrien, O.; Iffil, J.J.; et al. The Spectrum of Neurobehavioral Sequelae after Repetitive Mild Traumatic Brain Injury: A Novel Mouse Model of Chronic Traumatic Encephalopathy. J. Neurotrauma 2014, 31, 1211–1224. [CrossRef]

49. Lucke-Wold, B.P.; Turner, R.C.; Logsdon, A.F.; Bailes, J.E.; Huber, J.D.; Rosen, C.L. Linking traumatic brain injury to chronic traumatic encephalopathy: Identification of potential mechanisms leading to neurofibrillary tangle development. J. Neurotrauma 2014, 31, 1129–1138. [CrossRef]

50. Rubenstein, R.; Sharma, D.R.; Chang, B.; Oumata, N.; Cam, M.; Vaucelle, L.; Lindberg, M.F.; Chiu, A.; Wisniewski, T.; Wang, K.K.W.; et al. Novel Mouse Tauopathy Model for Repetitive Mild Traumatic Brain Injury: Evaluation of Long-Term Effects on Cognition and Biomarker Levels After Therapeutic Inhibition of Tau Phosphorylation. Front. Neurol. 2019, 10, 124. [CrossRef] [PubMed]

51. Petraglia, A.L.; Plog, B.A.; Dayawansa, S.; Dashnaw, M.L.; Czerniecka, K.; Walker, C.T.; Chen, M.; Hyrien, O.; Iffil, J.J.; Deane, R.; et al. The pathophysiology underlying repetitive mild traumatic brain injury in a novel mouse model of chronic traumatic encephalopathy. Surg. Neurol. Int. 2014, 5, 184. [CrossRef] [PubMed]

52. Namjoshi, D.R.; Cheng, W.H.; McInnes, K.A.; Martens, K.M.; Carr, M.; Wilkinson, A.; Fan, J.; Robert, J.; Hayat, A.; Cripston, P.A.; et al. Merging pathology with biomechanics using CHIMERA (Closed-Head Impact Model of Engineered Rotational Acceleration): A novel, surgery-free model of traumatic brain injury. Mol. Neurodegener. 2014, 9, 55. [CrossRef] [PubMed]

53. Cheng, W.H.; Martens, K.M.; Bashir, A.; Cheung, H.; Stukas, S.; Gibbs, E.; Namjoshi, D.R.; Button, E.B.; Wilkinson, A.; Barron, C.J.; et al. CHIMERA repetitive mild traumatic brain injury induces chronic behavioural and neuropaathological phenotypes in wild-type and APP/PS1 mice. Alzheimers Res. Ther. 2019, 11, 6. [CrossRef] [PubMed]

54. Lucke-Wold, B.; Seidel, K.; Udo, R.; Ormolu, B.; Ornstein, M.; Nolan, R.; Rosen, C.; Ross, J. Role of Tau Acetylation in Alzheimer’s Disease and Chronic Traumatic Encephalopathy: The Way Forward for Successful Treatment. J. Neurol. Neurosurg. 2017, 4, 1129–1138.

55. Min, S.W.; Chen, X.; Tracy, T.E.; Li, Y.; Zhou, Y.; Wang, C.; Shirakawa, K.; Minami, S.S.; Defensor, E.; Mok, S.A.; et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat. Med. 2015, 21, 1154–1162. [CrossRef]

56. Lagraoui, M.; Sukumar, G.; Latoche, J.R.; Maynard, S.K.; Dalgaard, C.L.; Schaefer, B.C. Salisalate treatment following traumatic brain injury reduces inflammation and promotes a neuroprotective and neuroregenerative response with concomitant functional recovery. Brain Behav. Immun. 2017, 61, 96–109. [CrossRef] [PubMed]

57. Shirakawa, K.; Wang, L.; Man, N.; Maksimoska, J.; Sorum, A.W.; Lim, H.W.; Lee, I.S.; Shimazu, T.; Newman, J.C.; Schroder, S.; et al. Salicylate, difunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity. eLife 2016, 5, e11156. [CrossRef] [PubMed]

58. Talley Watts, L.; Long, J.A.; Chemello, J.; Van Koughnet, S.; Fernandez, A.; Huang, S.; Shen, Q.; Duong, T.Q. Methylene blue is neuroprotective against mild traumatic brain injury. J. Neurotrauma 2014, 31, 1063–1071. [CrossRef]

59. Vekaria, H.J.; Talley Watts, L.; Lin, A.-L.; Sullivan, P.G. Targeting mitochondrial dysfunction in CNS injury using Methylene Blue; still a magic bullet? Neurochem. Int. 2017, 109, 117–125. [CrossRef]

60. Fenn, A.M.; Skendelas, J.P.; Moussa, D.N.; Muccigrosso, M.M.; Popovich, P.G.; Lifshitz, J.; Eiferman, D.S.; Godbout, J.P. Methylene blue attenuates traumatic brain injury-associated neuroinflammation and acute depressive-like behavior in mice. J. Neurotrauma 2015, 32, 127–138. [CrossRef]

61. Zhao, M.; Liang, F.; Xu, H.; Yan, W.; Zhang, J. Methylene blue exerts a neuroprotective effect against traumatic brain injury by promoting autophagy and inhibiting microglial activation. Mol. Med. Rep. 2016, 13, 13–20. [CrossRef]

62. Tucker, D.; Lu, Y.; Zhang, Q. From Mitochondrial Function to Neuroprotection—an Emerging Role for Methylene Blue. Mol. Neurobiol. 2018, 55, 5137–5153. [CrossRef] [PubMed]

63. Talley Watts, L.; Long, J.A.; Boggs, R.C.; Manga, H.; Huang, S.; Shen, Q.; Duong, T.Q. Delayed Methylene Blue Improves Lesion Volume, Multi-Parametric Quantitative Magnetic Resonance Imaging Measurements, and Behavioral Outcome after Traumatic Brain Injury. J. Neurotrauma 2016, 33, 194–202. [CrossRef] [PubMed]

64. Shen, J.; Xin, W.; Li, Q.; Gao, Y.; Yuan, L.; Zhang, J. Methylene Blue Reduces Neuronal Apoptosis and Improves Blood-Brain Barrier Integrity After Traumatic Brain Injury. Front. Neurol. 2019, 10, 1133. [CrossRef] [PubMed]

65. Cohen, T.J.; Guo, J.L.; Hurtado, D.E.; Kwong, L.K.; Mills, I.P.; Trojanowski, J.Q.; Lee, V.M.Y. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat. Commun. 2011, 2, 252. [CrossRef] [PubMed]

66. Min, S.-W.; Cho, S.-H.; Zhou, Y.; Schroeder, S.; Haroutunian, V.; Seeley, W.W.; Huang, E.J.; Shen, Y.; Masliah, E.; Mukherjee, C.; et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 2010, 67, 953–966. [CrossRef] [PubMed]
67. Rojo, A.I.; Sagarra, M.R.; Cuadrado, A. GSK-3beta down-regulates the transcription factor Nrf2 after oxidant damage: Relevance to exposure of neuronal cells to oxidative stress. *J. Neurochem.* 2008, 105, 192–202. [CrossRef] [PubMed]

68. Rankin, C.A.; Sun, Q.; Gamblin, T.C. Tau phosphorylation by GSK-3beta promotes tangle-like filament morphology. *Mol. Neurodegener.* 2007, 2, 12. [CrossRef] [PubMed]

69. Hernandez, F.; Lucas, J.J.; Avila, J. GSK3 and tau: Two convergence points in Alzheimer’s disease. *J. Alzheimers Dis.* 2013, 33 (Suppl. 1), S141–S144. [CrossRef]

70. Cuadrado, A.; Kügler, S.; Lastres-Becker, I. Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy. *Redox Biol.* 2018, 14, 522–534. [CrossRef]

71. Dash, P.K.; Johnson, D.; Clark, J.; Orsi, S.A.; Zhang, M.; Zhao, J.; Grill, R.J.; Moore, A.N.; Pati, S. Involvement of the glycogen synthase kinase-3 signaling pathway in TBI pathology and neurocognitive outcome. *PLoS ONE* 2011, 6, e24648. [CrossRef] [PubMed]

72. Shapira, M.; Licht, A.; Milman, A.; Pick, C.G.; Shohami, E.; Eldar-Finkelman, H. Role of glycogen synthase kinase-3beta in early depressive behavior induced by mild traumatic brain injury. *Mol. Cell. Neurosci.* 2007, 34, 571–577. [CrossRef]

73. Yu, F.; Zhang, Y.; Chiu, C.T.; Zhang, Y.; Chiang, D.M. Lithium ameliorates neurodegeneration, suppresses neuroinflammation, and improves behavioral performance in a mouse model of traumatic brain injury. *J. Neurotrauma* 2012, 29, 362–374. [CrossRef]

74. Yu, F.; Wang, Z.; Tchantchou, F.; Chiu, C.T.; Zhang, Y.; Chiang, D.M. Lithium ameliorates neurodegeneration, suppresses neuroinflammation, and improves behavioral performance in a mouse model of traumatic brain injury. *J. Neurotrauma* 2012, 29, 362–374. [CrossRef]

75. Yu, F.; Wang, Z.; Tanaka, M.; Chiu, C.T.; Leeds, P.; Zhang, Y.; Chiang, D.M. Posttraumatic coetreatment with lithium and valproate: Reduction of lesion volume, attenuation of blood-brain barrier disruption, and improvement in motor coordination in mice with traumatic brain injury. *J. Neurosurg.* 2013, 119, 766–773. [CrossRef]

76. Zhu, Z.F.; Wang, Q.G.; Han, B.J.; William, C.P. Neuroprotective effect and cognitive outcome of chronic lithium on traumatic brain injury in mice. *Brain Res.* 2010, 83, 272–277. [CrossRef]

77. Leeds, P.R.; Yu, F.; Wang, Z.; Chiu, C.T.; Zhang, Y.; Leng, Y.; Linares, G.R.; Chiang, D.-M. A new avenue for lithium: Intervention in traumatic brain injury. *ACS Chem. Neurosci.* 2014, 5, 422–433. [CrossRef] [PubMed]

78. Nassir Ghaemi, S.; Mauer, S.; Omalu, B.I. Lithium treatment for chronic traumatic encephalopathy: A proposal. *Bipolar Disord.* 2019, 21, 104–105. [CrossRef]

79. Kondo, A.; Shahpasand, K.; Mannix, R.; Quin, J.; Moncaster, J.; Chen, C.H.; Yao, Y.; Lin, Y.M.; Driver, J.A.; Sun, Y.; et al. Anti-Phospho-Tau Gene Therapy for Chronic Traumatic Encephalopathy. *Hum. Gene Ther.* 2015, 26, 140–151. [CrossRef] [PubMed]

80. Wible, E.F.; Laskowitz, D.T. Statins in traumatic brain injury. *Neurotherapeutics* 2010, 7, 62–73. [CrossRef] [PubMed]

81. Rankin, C.A.; Sun, Q.; Gamblin, T.C. Tau phosphorylation by GSK-3beta promotes tangle-like filament morphology. *PLoS ONE* 2011, 5, e11383. [CrossRef]

82. Nobuhara, C.K.; DeVos, S.L.; Commins, C.; Wegmann, S.; Moore, B.D.; Roe, A.D.; Costantino, I.; Frosch, M.P.; Pitstick, R.; Carlson, G.A.; et al. Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro. *Am. J. Pathol.* 2017, 187, 1399–1412. [CrossRef]

83. Lu, K.P.; Kondo, A.; Albayram, O.; Herbert, M.K.; Liu, H.; Zhou, X.Z. Potential of the Antibody Against cis-Phosphorylated Tau in the Early Diagnosis, Treatment, and Prevention of Alzheimer Disease and Brain Injury. *JAMA Neurol.* 2016, 73, 1356–1362. [CrossRef] [PubMed]

84. Shapira, M.; Licht, A.; Milman, A.; Pick, C.G.; Shohami, E.; Eldar-Finkelman, H. Role of glycogen synthase kinase-3beta in early depressive behavior induced by mild traumatic brain injury. *J. Neurosurg.* 2013, 119, 766–773. [CrossRef]

85. Xu, F.; Zhang, Y.; Chiang, D.M. Lithium reduces BACE1 overexpression, β amyloid accumulation, and spatial learning deficits in mice with traumatic brain injury. *J. Neurotrauma* 2012, 29, 2342–2351. [CrossRef] [PubMed]

86. Kondo, A.; Shahpasand, K.; Mannix, R.; Qiu, J.; Moncaster, J.; Chen, C.H.; Yao, Y.; Lin, Y.M.; Driver, J.A.; Sun, Y.; et al. Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy. *Nature* 2015, 523, 431–436. [CrossRef] [PubMed]

87. Lu, K.P.; Kondo, A.; Albayram, O.; Herbert, M.K.; Liu, H.; Zhou, X.Z. Potential of the Antibody Against cis-Phosphorylated Tau in the Early Diagnosis, Treatment, and Prevention of Alzheimer Disease and Brain Injury. *JAMA Neurol.* 2016, 73, 1356–1362. [CrossRef] [PubMed]

88. Houck, A.; Kondo, A.; Lu, K.P. Cis-p-tau directly links traumatic brain injury with chronic traumatic encephalopathy and Alzheimer’s disease, but can be blocked by antibody (P5.221). *Neurology* 2017, 88 (Suppl. 16).

89. Pozdnyakov, D.I.; Miroshnichenko, K.A.; Voronkov, A.V.; Kovaleva, T.Y.G. The Administration of the New Pyrimidine Derivative-4-(2-[3,4-Dimethoxyphenyl]-Vinyl]-6-Ethyl-4-Oxo-5-Phenyl-4H-Pyrimidine-1-I]Benzsulfamide Restores the Activity of Brain Cells in Experimental Chronic Traumatic Encephalopathy by Maintaining Mitochondrial Function. *Medicina* 2019, 55, 386. [CrossRef]

90. Logsdon, A.F.; Lucke-Wold, B.P.; Nguyen, L.; Matsumoto, R.R.; Turner, R.C.; Rosen, C.L.; Huber, J.D. Sulforbrin reduces oxidative stress, neuroinflammation and impulsive-like behavior in a rodent model of traumatic brain injury. *Brain Res.* 2016, 1643, 140–151. [CrossRef]

91. Wang, Y.; Liu, Y.; Nham, A.; Sherbaf, A.; Quach, D.; Yahya, E.; Ranburger, D.; Bi, X.; Baudry, M. Calpain-2 as a therapeutic target in repeated concussion-induced neuropathy and behavioral impairment. *Sci. Adv.* 2020, 6. [CrossRef]
92. McDougall, A.; Bayley, M.; Munce, S.E. The ketogenic diet as a treatment for traumatic brain injury: A scoping review. Brain Inj. 2018, 32, 416–422. [CrossRef] [PubMed]

93. Elbin, R.J.; Sufrinko, A.; Schatz, P.; French, J.; Henry, L.; Burkhart, S.; Collins, M.W.; Kontos, A.P. Removal from Play After Concussion and Recovery Time. Pediatrics 2016, 138, e20160910. [CrossRef]

94. Meehan, W.P., 3rd; Zhang, J.; Mannix, R.; Whalen, M.J. Increasing recovery time between injuries improves cognitive outcome after repetitive mild concussive brain injuries in mice. Neurosurgery 2012, 71, 885–891. [CrossRef]

95. Zhang, J.; Teng, Z.; Song, Y.; Hu, M.; Chen, C. Inhibition of monoacylglycerol lipase prevents chronic traumatic encephalopathy-like neuropathology in a mouse model of repetitive mild closed head injury. J. Cereb. Blood Flow Metab. 2015, 35, 443–453. [CrossRef] [PubMed]

96. Panikashvili, D.; Shein, N.A.; Mechoulam, R.; Trembovler, V.; Kohen, R.; Alexandrovich, A.; Shohami, E. The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol. Dis. 2006, 22, 257–264. [CrossRef] [PubMed]

97. Gangolli, M.; Holleran, L.; Hee Kim, J.; Stein, T.D.; Alvarez, V.; McKee, A.C.; Brody, D.L. Quantitative validation of a nonlinear histology-MRI coregistration method using generalized Q-sampling imaging in complex human cortical white matter. Neuroimage 2017, 153, 152–167. [CrossRef] [PubMed]

98. Ruprecht, R.; Scheurer, E.; Lenz, C. Systematic review on the characterization of chronic traumatic encephalopathy by MRI and MRS. J. Magn. Reson. Imaging 2019, 49, 212–228. [CrossRef]

99. Stern, R.A. The DIAGNOSE-CTE Research Project (DIAGNOSE-CTE); Boston University: Boston, MA, USA, 2020.

100. Wang, K.K.; Yang, Z.; Zhu, T.; Shi, Y.; Rubenstein, R.; Tyndall, J.A.; Manley, G.T. An update on diagnostic and prognostic biomarkers for traumatic brain injury. Expert Rev. Mol. Diagn. 2018, 18, 165–180. [CrossRef] [PubMed]

101. Zetterberg, H.; Blennow, K. Chapter 30—Chronic traumatic encephalopathy: Fluid biomarkers. In Handbook of Clinical Neurology; Hainline, B., Stern, R.A., Eds.; Elsevier: Amsterdam, The Netherlands, 2018; pp. 323–333.

102. Aalipour, A.; Chuang, H.Y.; Murty, S.; D’Souza, A.L.; Park, S.M.; Gulati, G.S.; Patel, C.B.; Beinat, C.; Simonetta, F.; Martiníć, I.; et al. Engineered immune cells as highly sensitive cancer diagnostics. Nat. Biotechnol. 2019, 37, 531–539. [CrossRef]

103. Breen, P.W.; Krishnan, V. Recent Preclinical Insights into the Treatment of Chronic Traumatic Encephalopathy. Front. Neurosci. 2020, 14, 616. [CrossRef]

104. Fitzgerald, N.D.; Cammack, K.M. Chronic Traumatic Encephalopathy: A Review of Clinical Diagnosis, Animal Models, Sex Differences, and A Revised Return-to-Play Protocol. Impulse Prem. J. Undergrad. Publ. Neurosci. 2017, 2017, 1–16.